Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance
CRANBURY, NJ–(BUSINESS WIRE)– Rocket Pharmaceuticals (NASDAQ:RCKT), a clinical-stage company developing an integrated and sustainable pipeline of gene therapies for rare childhood diseases, today announced the appointment of Jessie Yeung as vice president of investors and corporate finance. Ms. Yeung brings over 15 years of experience in investor relations, corporate finance and capital markets across all industries, including biopharmaceuticals and financials. She will be responsible for leading the investor relations function and capital markets strategy.
“I am thrilled to welcome Jessie to Rocket as we continue to advance our pipeline of world-class gene therapy clinical programs and achieve several key milestones as a company, including our first high-profile reads this year. “said Gaurav Shah, Chairman and CEO of Rocket Pharma. “Jessie’s breadth of relationships and experience with the investment community and wealth of her financial expertise will be invaluable to our investors, existing and new, as we continue our growth trajectory.” Jessie’s leadership will be instrumental in communicating Rocket’s unique approach to gene therapy and progress in our relentless pursuit of innovative gene therapy treatments for rare and devastating diseases.
Prior to joining Rocket, Ms. Yeung was responsible for corporate finance and investor relations at Legend Biotech. There, she developed the company’s comprehensive investor relations strategy leading to exceptional investor relations, while helping to raise over $1 billion through private placements and public offerings, as well than launching the biggest biotech IPO of 2020. Prior to Legend Biotech, she covered the big cap on the biotech sector as an equity research analyst at Bank of America Merrill Lynch, as well as than in the pharmaceutical sector at Wells Fargo and the retail sector at JP Morgan. During her tenure in equity research, Ms. Yeung developed an extensive network of investors. Earlier in her career, Ms. Yeung worked at JP Morgan for over 10 years, where she held positions in corporate finance, including financial planning and analysis, product and valuation control, business development and risk management.
“It is a tremendous honor to join the passionate and talented team at Rocket, given its unique and exciting pipeline of cross-platform clinical programs and its leadership in the growing field of gene therapy,” said Ms. Yeung. . “I am excited to continue to engage with the investment community to tell the Rocket story and create long-term shareholder value.”
Ms. Yeung holds a Bachelor of Business Administration from Carnegie Mellon University and an MBA from Columbia Business School.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and sustainable pipeline of genetic therapies that address the root cause of complex and rare childhood disorders. The Company’s platform-independent approach enables it to design the best therapy for each indication, creating potentially transformative options for patients with rare genetic diseases. Rocket’s clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure and potentially cancer, leukocyte adhesion deficiency-I (LAD-I), a serious pediatric genetic disease that causes recurrent and life-threatening infections, and pyruvate kinase deficiency (PKD), a rare, monogenic disease of red blood cells that results in increased destruction red blood cells and mild to life-threatening anemia. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon’s disease, a devastating pediatric heart failure. For more information on Rocket, please visit www.rocketpharma.com.
Rocket Caution Regarding Forward-Looking Statements
Various statements in this release regarding Rocket’s future expectations, plans and outlook, including, without limitation, Rocket’s expectations regarding its 2022 guidance in light of COVID-19, product safety and efficacy candidates Rocket is developing to treat Fanconi anemia (FA), Leukocyte adhesion deficiency-I (LAD-I), Pyruvate kinase deficiency (PKD), and Danon’s disease, the expected timeline and data readings from the trials Rocket’s ongoing and planned clinical trials, Rocket’s plans for advancing its Danon disease program following the lifting of the FDA clinical halt and the safety, efficacy and timing of preclinical studies and related clinical trials, may constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to risk, incert Substantial studies and hypotheses. You should not rely on these forward-looking statements, which often include words such as “believe”, “expect”, “anticipate”, “intend”, “plan”, “provide”, ” estimate”, “seek”, “”will”, “may”, “suggest” or similar terms, variations of these terms or the negative form of these terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable , Rocket cannot guarantee such results. Actual results may differ materially from those indicated by these forward-looking statements due to a variety of important factors, including, without limitation, Rocket’s ability to monitor the impact of COVID- 19 on its business operations and to take steps to ensure the safety of patients, families and employees, the interest of patients and families in participating in each of Rocket’s ongoing trials, our expectations regarding delays and I’ impact of COVID-19 on clinical sites, patient recruitment, trial timelines and data readout, our expectations regarding our drug supply for our ongoing and planned trials, actions of regulatory agencies, which may affect the initiation, timing and progress of preclinical studies and clinical trials of its product candidates, Rocket’s reliance on third parties for the development, manufacture, marketing, sale and distribution of the product candidates -revenues, the outcome of litigation and unanticipated expenses, and such risks further discussed in the section titled “Risk Factors” in Rocket’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed November 5, 2021 with the SEC. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date they are made, and Rocket undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. .